BioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call Transcript

Feb. 26, 2021 3:47 AM ETBioMarin Pharmaceutical Inc. (BMRN) StockBMRN
SA Transcripts
153.96K Followers

Q4: 2021-02-25 Earnings Summary

EPS of $0.21 beats by $0.03
 | Revenue of $452.12M (-0.51% Y/Y) beats by $11.97M

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET

Company Participants

Traci McCarty – Vice President of Investor Relations
J.J. Bienaime – Chairman and Chief Executive Officer
Jeff Ajer – Executive Vice President and Chief Commercial Officer
Hank Fuchs – President, Worldwide Research and Development
Brian Mueller – Executive Vice President and Chief Financial Officer

Conference Call Participants

Kripa Devarakonda – Truist Securities
Cory Kasimov – JPMorgan
Salveen Richter – Goldman Sachs
Phil Nadeau – Cowen & Company
Chris Raymond – Piper Sandler
Geoff Meacham – Bank of America
Thor Nagel – Stifel
Akash Tewari – Wolfe Research
Kennen MacKay – RBC Capital Markets
Gena Wang – Barclays
Kostas Biliouris – Morgan Stanley
Liana Moussatos – Wedbush Securities
Michelle Gilson – Canaccord Genuity

Operator

Welcome to the BioMarin Fourth Quarter and Full Year 2020 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Traci.

Traci McCarty

Thank you, Nicola, and thank you everyone for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.

Results may differ materially depending on progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical markets and developments by competitors, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission such as 10-Q, 10-K and 8-K reports.

On the call remotely from BioMarin management today are J.J. Bienaime, Chairman and Chief Executive Officer; Jeff Ajer, Executive Vice President and Chief Commercial Officer; Hank Fuchs, President, Worldwide Research and Development; and Brian Mueller, Executive Vice President and Chief Financial Officer. We do hope to keep this call

Recommended For You

About BMRN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BMRN